Tao Zhu

Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial

Shipo Wu, Jianying Huang, Zhe Zhang et al. · The Lancet Infectious Diseases · 2021 · 300 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +15

Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial

Scott A. Halperin, Lingyun Ye, Donna MacKinnon‐Cameron et al. · The Lancet · 2021 · 237 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Latent tuberculosis infection in rural China: baseline results of a population-based, multicentre, prospective cohort study

Lei Gao, Wei Lu, Liqiong Bai et al. · The Lancet Infectious Diseases · 2015 · 229 citations

Public Health, Infectious Diseases, Preventive Medicine +16

Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial

Fengcai Zhu, Lihua Hou, Jingxin Li et al. · The Lancet · 2015 · 187 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +14

Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial

Jingxin Li, Shipo Wu, Xiling Guo et al. · The Lancet Respiratory Medicine · 2022 · 170 citations · Full text

Life Sciences, Immunology, Infectious Diseases +15